AMAG Pharmaceuticals has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for bremelanotide, which AMAG in-licensed from Palatin Technologies, Inc. in February 2017.    Bremelanotide is a first-in-class melanocortin 4 receptor agonist developed to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It has a novel mechanism of action that activates the endogenous melanocortin pathways in the brain involved in the body...